Eli Lilly and Co Diabetes & Obesity Update at ADA Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Two questions for me, please. Firstly, following on from prior questions on pricing and access, interested to hear your view conceptually over time. Do you expect the net price of GLP-1 in obesity to fall towards that of those in diabetes? Do you see those 2 diseases today as distinct markets or the lines now between obesity and diabetes is fading from a prescribing, pricing and reimbursement point of view? And then secondly, on the pipeline, one of your partners, Regor Therapeutics, published some Phase I data for its oral GLP-1 at ADA this year. I think that, that asset has now started Phase II. And I'd just be interested to understand whether that's an asset that falls under your collaboration agreement. Lauren Zierke;Senior Director of Investor Relations Thanks, Kerry. We'll go to Mike to your first question on price and Ruth for your second question on partnership.